Compare Incyte Corporation (INCY) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ABRDN Physical Gold Shares ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B). The key difference: Incyte Corporation is far larger — about 3.3× ABRDN Physical Gold Shares ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| INCY | SGOL | |
|---|---|---|
Market Cap | $22.85B | $7.03B |
Volume | 1,927,029 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.93 | $51.41 |
52-Week Low | $83.80 | $37.54 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
SGOL trades at $39.31, up 0.74% today, while technical indicators show a bearish bias with moving averages and ADX signaling sell conditions. The stock lacks key financial ratio data such as P/E and P/B, limiting fundamental clarity. Recent gold-related news highlights pressure from rising Treasury yields and a firm dollar, though softer inflation data has provided some support.
The outlook remains cautious due to macroeconomic headwinds and incomplete financial disclosures. Risks include interest rate sensitivity and gold price volatility. Investors should seek updated SEC filings for fundamental metrics before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
